Affimed N.V.

+0.10 (+1.93%)

Affimed Announces Publication Of Final Results Of Its Innate Cell Engager Candidate Afm13 In Combination With Msd’S Anti-Pd-1 Therapy Keytruda®

Published: 11/19/2020 21:12 GMT
Affimed NV (AFMD) - Affimed Announces Publication of Final Study Results of Its Innate Cell Engager Candidate Afm13 in Combination With Msd’s Anti-pd-1 Therapy Keytruda® (pembrolizumab) in Blood.
Affimed NV - Safety Profile for Combination Was Described As Well-tolerated and Similar to Known Profiles for Each Agent Alone.
Affimed NV - Phase 1b Study Showed a Crr of 46%, Orr of 88% at Recommended Dose Level in Patients With Relapsed/refractory (r/r) Hodgkin Lymphoma.
Affimed NV - Most Adverse Events Were Low Grade, Remained Manageable With Standard-of-care Therapies in Phase 1b Afm13 With Keytruda Study.